Oncodesign Precision Medicine and Ksilink Partner to Screen Nanocyclix® Library for CNS Therapeutics
Key Insights
Oncodesign Precision Medicine (search) and Ksilink (search) announced a research collaboration to evaluate OPM's Nanocyclix® (search) library using advanced high-throughput phenotypic screening platforms for neurodegenerative and neurodevelopmental disorders (search).
The partnership combines Ksilink (search)'s AI-assisted phenotyping technology that analyzes patient-derived cells with OPM's proprietary macrocyclic small molecules (search) known for high selectivity and potency in kinases (search).
The collaboration aims to identify first-in-class therapeutic candidates by capturing subtle cellular pathomorphologies directly from patient cells, potentially addressing significant unmet medical needs in central nervous system diseases (search).
Oncodesign Precision Medicine (search) (OPM) and Ksilink (search) have launched a research collaboration to evaluate OPM's Nanocyclix® (search) chemical library using advanced phenotypic screening platforms for central nervous system disorders. The partnership aims to identify new small molecule modulators that may address significant unmet medical needs in neurodegenerative and neurodevelopmental disorders (search).
Advanced Screening Technology Integration
Under the collaboration, Ksilink (search) will evaluate OPM's Nanocyclix® (search) library using its high-throughput phenotypic screening platforms. The approach involves analyzing molecular effects directly on patient-derived cells using a unique AI-assisted phenotyping method applicable across multiple therapeutic areas.
Ksilink (search)'s high-content phenotyping technologies enable the capture of subtle cellular pathomorphologies relevant to the disease under study, directly from patient cells. Combined with OPM's Nanocyclix® (search) technology, a proprietary platform of macrocyclic small molecules (search) known for their high selectivity and potency in kinases (search), the partnership aims to accelerate discovery of first-in-class therapeutic candidates.
Strategic Focus on CNS Disorders
"We are pleased to initiate this collaboration with Oncodesign Precision Medicine (search) to explore the potential of Nanocyclix® (search) molecules in our models derived from patients with central nervous system diseases (search)," said Antoine de Lacombe, CEO of Ksilink (search). "Our ambition is to highlight biological effects that are undetectable by traditional screening approaches in order to identify innovative therapeutic candidates with an increased probability of clinical success."
Jan Hoflack, co-founder and CSO of Oncodesign Precision Medicine (search), emphasized the strategic alignment: "Our compound collection is ideally suited for this type of cell based phenotypic application, as our assets are highly potent and selective kinase inhibitors (search) with the required physicochemical properties to readily cross cell membranes. This collaboration aligns with our strategy to expand the application of Nanocyclix® (search) compounds into complex CNS disorders where innovation is urgently needed."
Platform Capabilities and Pipeline
Ksilink (search)'s innovative platform enables high-throughput screening of complex disease models that closely resemble patient reality. The company has screened more than 250,000 compounds and maintains proven expertise across several indications. Its CNS pipeline includes strategic programs in Parkinson's disease (search), autism (search) (Phelan-McDermid Syndrome (search)), and neuroinflammation (search).
OPM's Nanocyclix® (search) technology platform enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors (search). The company currently maintains 12,000 molecules in its library and utilizes AI to accelerate drug candidate discovery while reducing development costs.
Study Objectives and Potential Impact
The study will focus on obtaining early information on the efficacy and biological impact of certain Nanocyclix® (search) molecules in Ksilink (search) models that accurately reflect disease biology. The results of this collaboration could support additional preclinical development programs for both partners.
The combination of OPM's and Ksilink (search)'s innovative platforms has the potential to both identify novel molecular targets and therapeutic candidates to address unmet needs for complex neurological diseases, where the lack of relevant models and high failure rate of clinical trials represent major challenges.